



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Transfer and metabolism of cortisol by the isolated perfused human placenta

Citation for published version:

Stirrat, L, Sengers, B, Norman, J, Homer, N, Andrew, R, Lewis, R & Reynolds, R 2017, 'Transfer and metabolism of cortisol by the isolated perfused human placenta', *The Journal of Clinical Endocrinology & Metabolism (JCEM)*. <https://doi.org/10.1210/jc.2017-02140>

Digital Object Identifier (DOI):

[10.1210/jc.2017-02140](https://doi.org/10.1210/jc.2017-02140)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

The Journal of Clinical Endocrinology & Metabolism (JCEM)

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



Transfer and Metabolism of Cortisol by the Isolated Perfused Human Placenta

*Laura I Stirrat¹, *Bram G Sengers^{2,3}, Jane E Norman¹, Natalie Z.M Homer^{4,5}, Ruth Andrew^{4,5},
**Rohan M Lewis³ and **Rebecca M Reynolds^{1,5}

1. Tommy's Centre for Maternal and Fetal Health, MRC Centre for Reproductive Health,
University of Edinburgh

2. Bioengineering Science Research Group, Faculty of Engineering and the
Environment, University of Southampton, UK

3. Institute for Life Sciences, University of Southampton, UK.

4. Mass Spectrometry Core, Edinburgh Clinical Research Facility, University of
Edinburgh, UK

5. University/BHF Centre for Cardiovascular Science, University of Edinburgh, UK

*joint first author

**joint last author

Precis: Placental cortisol metabolism and transfer was studied using tracers and
computational modelling. This indicated that the placenta presents both metabolic and
physical barriers to cortisol transfer.

Stirrat LI et al

Corresponding author and person to whom reprint requests should be addressed:

Professor Rebecca Reynolds

University/BHF Centre for Cardiovascular Science

Queen's Medical Research Institute

47 Little France Crescent

Edinburgh EH16 4TJ

Phone: +44 131 2426762

Fax: +44 131 2426779

Email: R.Reynolds@ed.ac.uk

Funding: This work was supported by funding from Tommy's and the Medical Research Council (MR/N022556/1). We also acknowledge the support of the British Heart Foundation and the Mass Spectrometry Core of the Edinburgh Clinical Research Facility.

Disclosure statement: The author reports no conflicts of interest in this work.

ABSTRACT

Context: Fetal overexposure to glucocorticoids *in utero* is associated with fetal growth restriction and is postulated to be a key mechanism linking suboptimal fetal growth with cardiovascular disease in later life.

Objective: To develop a model to predict maternal-fetal glucocorticoid transfer. We hypothesised placental 11 β -HSD2 would be the major rate-limiting step in maternal cortisol transfer to the fetus.

Design: We used a deuterated cortisol tracer in the *ex vivo* placental perfusion model, in combination with computational modelling, to investigate the role of interconversion of cortisol and its inactive metabolite cortisone on transfer of cortisol from mother to fetus.

Participants: Term placentas were collected from five women with uncomplicated pregnancies, at elective caesarean delivery.

Intervention: Maternal artery of the isolated perfused placenta was perfused with D4-cortisol.

Main Outcome Measures: D4-cortisol, D3-cortisone and D3-cortisol were measured in maternal and fetal venous outflows.

Results: D4-cortisol, D3-cortisone and D3-cortisol were detected and increased in maternal and fetal veins as the concentration of D4-cortisol perfusion increased. D3-cortisone synthesis was inhibited when 11 β -HSD activity was inhibited. At the highest inlet concentration only 3.0% of the maternal cortisol was transferred to the fetal circulation, while 26.5% was metabolised and 70.5% exited via the maternal vein. Inhibiting 11 β -HSD activity increased the transfer to the fetus to 7.3% of the maternal input, while 92.7% exited via the maternal vein.

Conclusions: Our findings challenge the concept that maternal cortisol diffuses freely across the placenta and confirm that 11 β -HSD2 acts as a major 'barrier' to cortisol transfer to the fetus.

72 **Keywords:** Cortisol; placenta; 11 β -HSD2; cortisone; tracer

73 **Word count: 3564**

1. Introduction

Cortisol, the principal circulating glucocorticoid hormone in humans, is essential for normal fetal development and tissue maturation. Fetal overexposure to glucocorticoids *in utero* is associated with intrauterine growth restriction, [1] and is postulated to be a key mechanism linking suboptimal fetal growth with increased risk of cardiovascular disease in later life. [2] Better knowledge of the factors regulating cortisol transfer to the fetus is essential to understand the pathophysiology of fetal growth restriction and is also relevant for prescribing of antenatal steroids which are widely used in clinical management of women at threat of pre-term birth.

Maternal circulating cortisol levels rise 3-fold during pregnancy. [3] Although glucocorticoids are lipophilic and thus are believed to freely cross the placenta, fetal cortisol levels are 5 to 10-fold lower than maternal levels [4] due to the activity of the placental enzyme 11-beta-hydroxysteroid dehydrogenase-type 2 (11 β -HSD2) [5-7] which catalyses the conversion of active cortisol into inactive cortisone. In human placenta 11 β -HSD2 is localized to the syncytiotrophoblast, [7] which is the primary barrier between the mother and the fetus and thus prevents glucocorticoids accessing placental cells and the fetal compartment. [8] Indeed placental 11 β -HSD2 has been suggested to inactivate the majority of maternal glucocorticoids passing to the fetus in rodents [9] and in humans. [10] 11-beta-hydroxysteroid dehydrogenase-type 1 (11 β -HSD1), which regenerates cortisol from inactive cortisone, is undetectable in the syncytiotrophoblast, but is localized in the extravillous trophoblasts (situated near maternal circulation) and endothelial cells lining fetal capillaries in terminal villi. [11] Whether or not the activity of placental 11 β -HSD1 regenerates a substantial amount of cortisol or contributes significantly to maternal or fetal circulations is not well understood. With a number of studies demonstrating links between placental glucocorticoid transfer, sensitivity and metabolism and adverse outcomes in infancy, childhood and adolescence, [12,13] understanding of the regulatory mechanisms and rate-limiting steps of maternal-fetal cortisol transfer is essential in

100 order to identify whether there are any options for targeted intervention to improve pregnancy
101 outcomes.

102 Studies using the *ex vivo* dual perfused placental perfusion model together with computational
103 modelling have generated new mechanistic insights into placental amino acid and lipid transfer
104 from mother to fetus. [14-16] In the current study we used this combined experimental and
105 computational modelling approach to develop a model to explore placental cortisol metabolism
106 and transfer and its regulation. We hypothesised that activity of placental 11 β -HSD2 would be
107 the major rate limiting step in maternal cortisol transfer to the fetus.

108

2. Methods

Five term placentas from women with uncomplicated pregnancies were collected on ice immediately after delivery by elective caesarean section at the Royal Infirmary of Edinburgh, with ethical approval (REC09/S0704/3) and written informed consent. Elective caesarean sections were performed between 39-40 weeks of gestation.

A. Placental Perfusions

Placentas were perfused using the methodology of Schneider [17] as adapted in a previous study. [18] Non-recirculating maternal and fetal circulations were established in an isolated cotyledon within 30 minutes of delivery. The fetal circulation and maternal intervillous space were perfused with a modified Earle's bicarbonate buffer (EBB: 5 mmol L⁻¹ glucose, 1.8 mmol L⁻¹ CaCl₂, 0.4 mmol L⁻¹ MgSO₄, 116.4 mmol L⁻¹ NaCl, 5.4 mmol L⁻¹ KCl, 26.2 mmol L⁻¹, NaHCO₃, 0.9 mmol L⁻¹ NaH₂PO₄), with Heparin (25,000 units/L; Fannin, Northamptonshire, UK) and bovine serum albumin (BSA [Fraction V; 98 %], 2 g/L, Sigma, UK) added. Maternal perfusate was equilibrated with 95% air and 5% CO₂, and fetal perfusate with 95% N₂ and 5% CO₂ (BOC, UK). Maternal circulation was at 14 mL/min and fetal circulation at 6 mL/min using a peristaltic pump (Watson-Marlow, UK).

Approximately 2 mL of venous perfusate was collected from the maternal and fetal venous outflows, at 5-minute intervals. Fetal artery pressure was maintained between 40 – 70 mmHg and fetal venous return was > 95%. At the end of the experiments, the perfused mass was identified on the 'maternal side' by slight blanching. The perfused placental cotyledon was weighed. Cotyledon volume was calculated on the basis of 1 mL per g tissue. Samples of maternal and fetal perfusate fluid, un-perfused tissue and perfused tissue were stored at -80 °C until analysis.

B. Use of deuterated tracers to investigate cortisol metabolism

Cortisol metabolism by 11 β -HSD enzymes and transport between the maternal and fetal circulations was investigated using the stable isotope deuterium (D)-labelled tracer, [9,11,12,12 $^2\text{H}_4$]-cortisol "D4-cortisol" [19] which is converted to [9,12,12 $^2\text{H}_3$]-cortisone "D3-cortisone" by 11 β -HSD2. Measurement of [9,12,12 $^2\text{H}_3$]-cortisol "D3-cortisol", which is regenerated from D3-cortisone can be used to assess activity of 11 β -HSD1 (Figure 1). After an initial 'washout' period of 30 minutes, D4-cortisol (Steraloids, USA) was perfused into the maternal circulation with stepped increases in concentrations of 20 nM, 200 nM and 800 nM every 30 minutes. The 800 nM D4-cortisol concentration was considered to be representative of circulating maternal cortisol levels in the third trimester [20]. The HSD inhibitor carbenoxolone (Sigma, UK) was added to the perfusion solution in addition to 800 nM D4-cortisol in the final 30 minutes at a concentration of 1000 nM, as informed by a previous study. [10]

C. LC-MS/MS quantification

Endogenous (cortisol, cortisone) and deuterated (D4-cortisol, D3-cortisone and D3-cortisol) glucocorticoids were measured simultaneously by liquid chromatography tandem mass spectrometry (LC-MS/MS) using a Waters Acquity™ UPLC (Manchester, UK) liquid chromatography system followed by mass spectral detection on an ABSciex QTRAP® 5500 (Warrington, UK) operated in positive electrospray ionization mode. Mass spectral conditions are described in Supplementary Table 1 in conjunction with ion spray voltage (5500 V) and source temperature (700 °C).

D. Perfusate fluid extraction

Following enrichment of perfusate (500 μL) with the internal standard epi-cortisol (10 ng; Steraloids, USA) and dilution with water (500 μL) analytes were extracted using a Sep-Pak C18 40 mg 96-well plate (Waters, Manchester, UK). Plates were primed with methanol (1 mL), then EBB (1 mL) then samples (500 μL) were loaded and plates washed with water (1 mL).

Analytes were eluted from the plate using acetonitrile (1 mL) directly into a 2 mL deep well collection plate (Waters, UK). Eluants were dried under oxygen-free nitrogen (60 °C) using a 96-well Dry down apparatus, and reconstituted in mobile phase (30:70 methanol: water; 100 µL).

E. Tissue Extraction

Placental tissue (200 mg) was homogenized in 3 mL 7:2 methanol: water and enriched with internal standard epi-cortisol (10 ng, as above) before being centrifuged at 3200 g for 45 minutes at 4 °C. Supernatant was transferred to a clean glass vial and dried under oxygen-free nitrogen (60 °C) and reconstituted in water (5 mL). Analytes were extracted using Sep-Pak C18 360 mg Classic Cartridges (Waters). Cartridges were primed with 100% methanol (5 mL) followed by water (5 mL). Samples were added to cartridges and allowed to flow through with gravity. Cartridges were washed with water (5 mL), and analytes were eluted with 100% methanol (2 mL) into a 3.5 mL glass vial. Eluants were dried down under oxygen-free nitrogen (60 °C) and reconstituted in 100 µL mobile phase.

F. Liquid chromatography tandem mass spectrometry (LC-MS/MS)

Samples in the auto-sampler were maintained at 10 °C. Analytes were separated at 40 °C on an ACE Excel C18-AR column (100 x 2.1 mm, 1.7 µm; Hichrom Limited®, Berkshire, UK) at a flow rate of 0.5 mL/min. Samples in the auto-sampler and sample manager were maintained at 10 °C. Starting with 70% water with 0.1% formic acid (FA) (solution A) and 30% acetonitrile with 0.1% FA (solution B), maintained for 4 minutes followed by a 1-minute linear rise to 60% solution B, a subsequent rise to 90% solution B, before restoring to 30% solution B at 6.1 minutes. This condition was sustained for 1-minute to re-equilibrate.

The inter-assay precision of D4-Cortisol in perfusate fluid was 3.6% - 11.6%, and inter-assay accuracy was 93% - 103%. Inter-assay precision of D3-Cortisol in perfusate fluid was 8.8% - 17.3% and inter-assay accuracy was 98% - 101%. For placental tissue samples (which were

all analysed on the same day), intra-assay precision was 7.0% for D4-Cortisol, and 6.4% for D3-Cortisol.

The peak areas of deuterated steroids were corrected for the abundances of naturally occurring isotopomers at baseline. In addition, the peak area of D4-cortisol was corrected for interference from the M+4 isotopologue of cortisol and the M+1 isotopologue of D3-cortisol. There was no available standard for D3-cortisone, so concentrations were estimated using the calibration curve for cortisone and the 'fold-change' or 'units / mL' rather than concentration calculated. The peak area of D3-cortisol was corrected for interference from the M+3 isotopologue of cortisol.

G. Data analysis

Deuterated hormone levels were adjusted for flow rate and were normalised to tissue weight of the perfused cotyledon. D4-cortisol and D3-cortisol were reported in ng, and in the absence of a standard for accurate quantification, D3-cortisone was measured in arbitrary units.

H. Computational model for placental transfer

A compartmental modelling framework was adopted to model the placental transfer of cortisol and cortisone in the *ex-vivo* perfusion experiments, based on our previous work. [14,15,21] The model distinguishes three separate physiological compartments associated with the maternal, syncytiotrophoblast and fetal capillary volumes (Figure 1a). Each compartment is described as well mixed. Transfer between compartments is determined by the fluxes across the apical and basal membranes and assumed to occur by simple diffusion for both cortisol and cortisone. Metabolic conversion from cortisol to cortisone within the syncytiotrophoblast is described as unidirectional using Michaelis-Menten kinetics. Model equations were implemented in Matlab (R2016a) as outlined previously [14,15,21]. Details of the equations that resulted and model parameters are described in Supplementary Methods.

207 A sensitivity analysis was carried out in which the model parameters were varied with respect
208 to the values for the reference fit. The reported changes in placental transfer predicted by the
209 model were based on the steady state results at the highest maternal input concentration.

210

3. Results

Characterisation of subjects

The mean (sd) maternal age was 36.4 ± 6.3 years, mean gestational length was 277 ± 2 days ($39+4$ weeks ± 2 days), and mean birthweight was 3721 ± 223 g.

D4-cortisol, D3-cortisone and D3-cortisol levels

Figure 2 shows the levels of D4-cortisol, D3-cortisone and D3-cortisol (plotted data with error bars) in maternal and fetal veins increased as the concentration of D4-cortisol in the maternal artery perfusion increased. D4-cortisol (Figure 2a-b) and D3-cortisone (Figure 2c-d) were detected in maternal and fetal vein 5-minutes after commencement of D4-cortisol perfusion (20 nM) in the maternal artery. D3-cortisol (Figure 2e-f) was detected at 95-minutes into the experiment in the maternal vein (perfusion phase: 800 nM D4-cortisol), and at 75-minutes in the fetal vein (perfusion phase: 200 nM D4-cortisol). Variation in the D3-cortisol levels reflects both the fact that D3-cortisol levels were near the limit of detection, and technical considerations when collecting maternal side samples in the perfusion system where variation tends to be higher. The biggest increase in D4-cortisol and D3-cortisone levels occurred when maternal artery D4-cortisol perfusion increased from 200 nM to 800 nM. Levels of D3-cortisone in the maternal circulation were approximately 5-fold higher than in the fetal circulation. When carbenoxolone was added to the maternal artery perfusion, D4-cortisol levels further increased in maternal and fetal veins, and D3-cortisone synthesis was completely inhibited. D3-cortisol levels were around 300-fold lower than D4-cortisol in both maternal and fetal circulations, and were close to the assay limit of detection. Levels of D3-cortisol in the maternal circulation were approximately 2-3-fold higher than levels in the fetal circulation. Proportionately more of the produced D3-cortisol was released into the fetal circulation than maternal circulation, when compared with the proportion of D3-cortisol released into maternal

and fetal circulations. Samples of buffer obtained on completion of the 'washout' phase of the experiment confirmed that there were no remaining endogenous or labelled glucocorticoids within the tubing used for the circuit.

Placental model results

The results of the model fit of the average maternal and fetal D4-cortisol measurements demonstrated an excellent overall ability of the computational model to represent the experimental data (Figure 2). From the model the estimated effective membrane permeability constant $k_{MVM} = 0.011$ L/min for the maternal facing MVM and $k_{BM} = 0.0015$ L/min for the fetal facing BM. Thus the permeability of the MVM was estimated to be 7.4 times higher than that of the BM. The estimated maximum rate capacity for the conversion of cortisol into cortisone $V_{4F \rightarrow 3E}^{max} = 5.0$ nmol/min per cotyledon. At the highest inlet concentration only 3.0 % of the maternal cortisol input was transferred to the fetal circulation, while 26.5% was metabolised and the remaining 70.5% exited via the maternal vein. Inhibiting 11β -HSD activity increased the transfer to the fetus to 7.3% of the maternal input, while 92.7% exited via the maternal vein. Based on these results it can also be seen that enzyme metabolism reduced transfer to the fetus by 59%. Note that if there were no placental barrier and no metabolism then the maternal and fetal vein would have an output of respectively 70% and 30% of the maternal inlet, based on the difference in flow rates alone (i.e. if concentrations within the placenta were perfectly mixed). The comparison between the predicted D3-cortisone and the scaled experimental data is shown in figure 2. It can be observed that the relative steady state levels correspond well for the fetal D3-cortisone, while the maternal D3-cortisone shows some larger discrepancies. In addition, the model responds much more rapidly to changes in input conditions. In this respect, the sharp peak at $t = 150$ min predicted by the model is due to the absence of blocker in the washout buffer, which is assumed to take immediate effect in the model.

The results of the sensitivity analysis in figure 3 show that when varying single parameters the placental transfer of cortisol was affected most by changes in k_{BM} , the membrane permeability of the BM, and the metabolic conversion rate of cortisol into cortisone $V_{AF \rightarrow 3E}^{max}$. In addition, placental transfer was predicted to be moderately sensitive to k_{MVM} , the permeability of the MVM, and the maternal flow rate used in the experiment Q_m . Variations in K_m only had a small impact as the metabolism continued to operate in the saturated regime, while increasing the fetal flow rate Q_f used in the experiment was predicted to only have a minor effect on transfer. Steady state transfer was not sensitive to any of the compartment volumes, as expected. To evaluate the impact of the overall membrane permeability, an additional study was done in which k_{BM} and k_{MVM} were both varied simultaneously, demonstrating a considerably larger effect than for the permeability of each membrane separately (figure 3).

4. Discussion

The experiments performed in this study using a deuterated cortisol tracer in the *ex vivo* placental perfusion model allowed investigation of the role of interconversion of cortisol and its inactive metabolite cortisone on transfer of cortisol from mother to fetus at term. The application of computational modelling enabled interpretation of the transfer mechanisms that underlie these processes. Our findings challenge the concept that maternal cortisol diffuses freely across the placenta, confirm that 11 β -HSD2 acts as a major 'barrier' to cortisol transfer to the fetus and show preliminary evidence of local cortisol production within the placenta.

Addition of carbenoxolone (a potent HSD inhibitor) to the maternal artery perfusion, resulted in no further production of D3-cortisone. This supports the role of 11 β -HSD2 as a key player in the maternal barrier to fetal glucocorticoid exposure. The activity (but not mRNA) of 11 β -HSD2 has been shown to decrease in the last two weeks before parturition. [22] The placentas used in the experiments were obtained from elective caesarean sections at between 39-40 weeks gestation, so it is not known when parturition would have occurred in these pregnancies. The model allowed an estimation of the maximum capacity of 11 β -HSD2 for conversion of cortisol to cortisone as 5.0 nmol/min per cotyledon. It is not known what the capacity of 11 β -HSD2 would be if exposed to high levels of maternal glucocorticoids for more prolonged periods, but studies have demonstrated that 11 β -HSD2 mRNA and activity is down-regulated by maternal stress [23] and inflammatory diseases. [22] Further, inhibition of 11 β -HSD2 by maternal liquorice consumption has adverse consequences on child development [24,25]. Our study supports the premise that the adverse offspring outcomes are due to increased fetal glucocorticoid exposure as when 11 β -HSD2 was inhibited by carbenoxolone, transplacental passage of maternal cortisol to the fetal circulation was more than doubled.

Yet, even when 11 β -HSD activity was inhibited using carbenoxolone, less than 10% of maternal D4-cortisol crossed the placenta in our experiments. This observation challenges the concept that cortisol freely diffuses across the placenta, and suggests alternate mechanisms

to protect the fetus from high maternal cortisol levels in addition to the well described inactivation of cortisol by 11 β -HSD2. Three ABC-transporters; multidrug-resistant protein (MRP1, encoded by *ABCC1*), p-glycoprotein (P-gp, encoded by *ABCB1*) and breast-cancer-resistant protein (BCRP, encoded by *ABCG2*) are localised to placental syncytiotrophoblast, and the fetal vessel endothelium [26,27] consistent with the potential for active transport of cortisol in and out of the placenta. Further studies are needed to investigate the contribution of ABC transporters, levels of which are known to alter across gestation, [28-31] in regulating maternal cortisol transfer to the fetus and in particular to understand the kinetics of efflux transporters, which our preliminary observations suggest may also protect the fetus.

Further we observed approximately a 5-fold higher D3-cortisone release to the maternal circulation compared with the fetal circulation. It also needs to be considered that the physical process of cortisol diffusion across tissues may be more challenging than has been thought previously. In particular, in the placenta diffusion across the water filled villous stroma may prove a barrier to cortisol diffusion. This is consistent with the observation that cortisone was preferentially released into the maternal circulation (2:1 maternal:fetal circulation), and the lower placental to fetal permeability calculated within the model.

A novel finding is the observation of *de novo* placental cortisol synthesis, as evidenced by the detection of D3-cortisol in both maternal and fetal circulations. Though the absolute levels of D3-cortisol were low, this regeneration of cortisol may have local paracrine roles and increased placental 11 β -HSD1 mRNA levels have been associated with maternal depression and with altered infant regulatory behaviours. [12,13] Further, proportionately more D3-cortisol was transferred to the fetus than D3-cortisone, which is in line with localisation of 11 β -HSD1 to the endothelium. [11] The computational model provided a good overall representation of the experimental data under different experimental conditions. In general, the compartmental model showed a faster response due to the well-mixed assumption, but this did not affect the steady state levels. The model predicted that changing membrane permeability of the BM would affect placental transfer of cortisol. Placental transfer of lipids has been reported to be

increased in pre-eclampsia. [32] Further studies are required to investigate whether inflammatory conditions such as pre-eclampsia and preterm labour alter the permeability of the BM, and thus alter placental cortisol transfer.

Our study has several limitations. This study focused on cortisol concentrations in the maternal and fetal plasma, as these determine the gradient driving transfer. However, from a whole body perspective, it needs to be realised that the maternal plasma compartment is larger than the fetal compartment and this would need to be taken into account for more broadly focused models. Our experiments were conducted using EBB buffer and albumin. The findings may be altered *in vivo* with the presence of corticosteroid binding globulin (CBG), the primary binding protein for cortisol [33] and this should be considered in future studies. Including such binding effects would not affect the overall modelling results if the unbound fraction is constant in the concentration range used, but would become important if binding differs between compartments. We were also unable to accurately quantify D3-cortisone concentrations, as there are no available standards. Nevertheless, we were able to estimate fold-changes in D3-cortisone concentrations so this should not limit interpretation of the results. A caveat of the model is that it does not account for further interconversion of D3-cortisol to D3-cortisone, although the net values of D3-cortisol quantified were very low. We did not study other pathways of cortisol metabolism such as the A-ring reductase enzymes, although Benediktsson et al., 1997 found that the products of 5 β -reductase or 20 α / β -hydroxysteroid dehydrogenase did not co-elute with cortisol or cortisone in placental perfusion studies, suggesting that these pathways may not metabolise cortisol or cortisone in the placenta. The contribution of other potential metabolism pathway, such as via carbonyl reductase 1 [34] which is located in placenta, is also unknown. Direct measurement of arterial input concentrations would also have provided additional confidence to this analysis.

Further studies using this model could investigate in more detail the contribution of the fetal circulation to maternal cortisol levels. Regeneration of cortisol from cortisone could be studied by perfusing the fetal circuit with D2-cortisone [35], and measuring the regenerated cortisol in

the maternal or fetal circuits. The potential for free placental passage of cortisol from the fetal to maternal circuit could be studied by perfusing the fetal circuit with D4-cortisol and measuring D4-cortisol, D3-cortisone and D3-cortisol in the maternal circulation. Future studies utilising inhibitors of ABC transporters are also needed to assess their contribution to placental cortisol transport. While technically challenging, functional studies using early and mid-gestation tissue would be of value as cortisol exposure at earlier gestations is thought to influence fetal growth. [36,37] Our model may also be a helpful tool in predicting fetal effects of synthetic glucocorticoids such as dexamethasone and betamethasone, used clinically to promote fetal lung maturation when preterm delivery is anticipated.

To conclude, we have developed a model to predict maternal-fetal cortisol transfer, which can now be used in future experimental design. Further studies are now needed to refine and develop the model in order to improve understanding of the mechanisms underlying maternal-fetal cortisol transfer and the pathways to normal fetal growth.

5. Acknowledgements

Author Contributions

LS designed the study, conducted the placental perfusion experiments and laboratory analysis, interpreted data and wrote the manuscript. BG designed the study, conducted the computational modelling, interpreted data and wrote the manuscript. JN interpreted data. NH and RA advised with laboratory assay development and data interpretation. RL designed the study, conducted computational modelling, interpreted data and wrote the manuscript. RR designed the study, interpreted data and wrote the manuscript. All authors reviewed the manuscript.

6. References

1. Stewart PM, Rogerson FM, Mason JI. Type 2 11 beta-hydroxysteroid dehydrogenase messenger ribonucleic acid and activity in human placenta and fetal membranes: its relationship to birth weight and putative role in fetal adrenal steroidogenesis. *J Clin Endocrinol Metab* 1995; 80:885-890
2. Reynolds RM. Glucocorticoid excess and the developmental origins of disease: two decades of testing the hypothesis--2012 Curt Richter Award Winner. *Psychoneuroendocrinology* 2013; 38:1-11
3. Jung C, Ho JT, Torpy DJ, Rogers A, Doogue M, Lewis JG, Czajko RJ, Inder WJ. A longitudinal study of plasma and urinary cortisol in pregnancy and postpartum. *J Clin Endocrinol Metab* 2011; 96:1533-1540
4. Beitins IZ, Bayard F, Ances IG, Kowarski A, Migeon CJ. The metabolic clearance rate, blood production, interconversion and transplacental passage of cortisol and cortisone in pregnancy near term. *Pediatr Res* 1973; 7:509-519
5. Brown RW, Chapman KE, Edwards CR, Seckl JR. Human placental 11 beta-hydroxysteroid dehydrogenase: evidence for and partial purification of a distinct NAD-dependent isoform. *Endocrinology* 1993; 132:2614-2621
6. Brown RW, Diaz R, Robson AC, Kotelevtsev YV, Mullins JJ, Kaufman MH, Seckl JR. The ontogeny of 11 beta-hydroxysteroid dehydrogenase type 2 and mineralocorticoid receptor gene expression reveal intricate control of glucocorticoid action in development. *Endocrinology* 1996; 137:794-797
7. Krozowski Z, McGuire JA, Stein-Oakley AN, Dowling J, Smith RE, Andrews RK. Immunohistochemical localization of the 11 beta-hydroxysteroid dehydrogenase type II enzyme in human kidney and placenta. *J Clin Endocrinol Metab* 1995; 80:2203-2209

- 403 8. Chapman K, Holmes M, Seckl J. 11beta-hydroxysteroid dehydrogenases: intracellular gate-
404 keepers of tissue glucocorticoid action. *Physiol Rev* 2013; 93:1139-1206
- 405 9. Cottrell EC, Holmes MC, Livingstone DE, Kenyon CJ, Seckl JR. Reconciling the nutritional and
406 glucocorticoid hypotheses of fetal programming. *FASEB J* 2012; 26:1866-1874
- 407 10. Benediktsson R, Calder AA, Edwards CR, Seckl JR. Placental 11 beta-hydroxysteroid
408 dehydrogenase: a key regulator of fetal glucocorticoid exposure. *Clin Endocrinol (Oxf)* 1997;
409 46:161-166
- 410 11. Sun K, Yang K, Challis JR. Differential expression of 11 beta-hydroxysteroid dehydrogenase
411 types 1 and 2 in human placenta and fetal membranes. *J Clin Endocrinol Metab* 1997; 82:300-
412 305
- 413 12. Reynolds RM, Pesonen AK, O'Reilly JR, Tuovinen S, Lahti M, Kajantie E, Villa PM, Laivuori H,
414 Hamalainen E, Seckl JR, Raikkonen K. Maternal depressive symptoms throughout pregnancy
415 are associated with increased placental glucocorticoid sensitivity. *Psychol Med* 2015:1-8
- 416 13. Raikkonen K, Pesonen AK, O'Reilly JR, Tuovinen S, Lahti M, Kajantie E, Villa P, Laivuori H,
417 Hamalainen E, Seckl JR, Reynolds RM. Maternal depressive symptoms during pregnancy,
418 placental expression of genes regulating glucocorticoid and serotonin function and infant
419 regulatory behaviors. *Psychol Med* 2015; 45:3217-3226
- 420 14. Sengers BG, Please CP, Lewis RM. Computational modelling of amino acid transfer interactions
421 in the placenta. *Exp Physiol* 2010; 95:829-840
- 422 15. Panitchob N, Widdows KL, Crocker IP, Hanson MA, Johnstone ED, Please CP, Sibley CP, Glazier
423 JD, Lewis RM, Sengers BG. Computational modelling of amino acid exchange and facilitated
424 transport in placental membrane vesicles. *J Theor Biol* 2015; 365:352-364
- 425 16. Perazzolo S, Hirschmugl B, Wadsack C, Desoye G, Lewis RM, Sengers BG. The influence of
426 placental metabolism on fatty acid transfer to the fetus. *J Lipid Res* 2017; 58:443-454
- 427 17. Schneider H, Panigel M, Dancis J. Transfer across the perfused human placenta of antipyrine,
428 sodium and leucine. *Am J Obstet Gynecol* 1972; 114:822-828

- 429 **18.** Cleal JK, Brownbill P, Godfrey KM, Jackson JM, Jackson AA, Sibley CP, Hanson MA, Lewis RM.
 430 Modification of fetal plasma amino acid composition by placental amino acid exchangers in
 431 vitro. *J Physiol* 2007; 582:871-882
- 432 **19.** Andrew R, Smith K, Jones GC, Walker BR. Distinguishing the activities of 11beta-
 433 hydroxysteroid dehydrogenases in vivo using isotopically labeled cortisol. *J Clin Endocrinol*
 434 *Metab* 2002; 87:277-285
- 435 **20.** Stirrat LI, O'Reilly JR, Barr SM, Andrew R, Riley SC, Howie AF, Bowman M, Smith R, Lewis JG,
 436 Denison FC, Forbes S, Seckl JR, Walker BR, Norman JE, Reynolds RM. Decreased maternal
 437 hypothalamic-pituitary-adrenal axis activity in very severely obese pregnancy: Associations
 438 with birthweight and gestation at delivery. *Psychoneuroendocrinology* 2016; 63:135-143
- 439 **21.** Panitchob N, Widdows KL, Crocker IP, Johnstone ED, Please CP, Sibley CP, Glazier JD, Lewis
 440 RM, Sengers BG. Computational modelling of placental amino acid transfer as an integrated
 441 system. *Biochim Biophys Acta* 2016; 1858:1451-1461
- 442 **22.** Murphy VE, Clifton VL. Alterations in human placental 11beta-hydroxysteroid dehydrogenase
 443 type 1 and 2 with gestational age and labour. *Placenta* 2003; 24:739-744
- 444 **23.** O'Donnell KJ, Bugge Jensen A, Freeman L, Khalife N, O'Connor TG, Glover V. Maternal prenatal
 445 anxiety and downregulation of placental 11beta-HSD2. *Psychoneuroendocrinology* 2012;
 446 37:818-826
- 447 **24.** Raikkonen K, Pesonen AK, Heinonen K, Lahti J, Komsu N, Eriksson JG, Seckl JR, Jarvenpaa AL,
 448 Strandberg TE. Maternal licorice consumption and detrimental cognitive and psychiatric
 449 outcomes in children. *Am J Epidemiol* 2009; 170:1137-1146
- 450 **25.** Raikkonen K, Martikainen S, Pesonen AK, Lahti J, Heinonen K, Pyhala R, Lahti M, Tuovinen S,
 451 Wehkalampi K, Sammallahti S, Kuula L, Andersson S, Eriksson JG, Ortega-Alonso A, Reynolds
 452 RM, Strandberg TE, Seckl JR, Kajantie E. Maternal Licorice Consumption During Pregnancy and
 453 Pubertal, Cognitive, and Psychiatric Outcomes in Children. *Am J Epidemiol* 2017:1-12

- 454 26. St-Pierre MV, Serrano MA, Macias RI, Dubs U, Hoechli M, Lauper U, Meier PJ, Marin JJ.
455 Expression of members of the multidrug resistance protein family in human term placenta.
456 Am J Physiol Regul Integr Comp Physiol 2000; 279:R1495-1503
- 457 27. Yeboah D, Sun M, Kingdom J, Baczyk D, Lye SJ, Matthews SG, Gibb W. Expression of breast
458 cancer resistance protein (BCRP/ABCG2) in human placenta throughout gestation and at term
459 before and after labor. Can J Physiol Pharmacol 2006; 84:1251-1258
- 460 28. Iqbal M, Audette MC, Petropoulos S, Gibb W, Matthews SG. Placental drug transporters and
461 their role in fetal protection. Placenta 2012; 33:137-142
- 462 29. Kalabis GM, Kostaki A, Andrews MH, Petropoulos S, Gibb W, Matthews SG. Multidrug
463 resistance phosphoglycoprotein (ABCB1) in the mouse placenta: fetal protection. Biol Reprod
464 2005; 73:591-597
- 465 30. Pascolo L, Ferneti C, Pirulli D, Crovella S, Amoroso A, Tiribelli C. Effects of maturation on RNA
466 transcription and protein expression of four MRP genes in human placenta and in BeWo cells.
467 Biochem Biophys Res Commun 2003; 303:259-265
- 468 31. Sun M, Kingdom J, Baczyk D, Lye SJ, Matthews SG, Gibb W. Expression of the multidrug
469 resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases with
470 advancing gestation. Placenta 2006; 27:602-609
- 471 32. Huang X, Jain A, Baumann M, Korner M, Surbek D, Butikofer P, Albrecht C. Increased placental
472 phospholipid levels in pre-eclamptic pregnancies. Int J Mol Sci 2013; 14:3487-3499
- 473 33. Hammond GL. Plasma steroid-binding proteins: primary gatekeepers of steroid hormone
474 action. J Endocrinol 2016; 230:R13-25
- 475 34. Phillips RJ, Fortier MA, Lopez Bernal A. Prostaglandin pathway gene expression in human
476 placenta, amnion and choriodecidua is differentially affected by preterm and term labour and
477 by uterine inflammation. BMC Pregnancy Childbirth 2014; 14:241

- 478 **35.** Hughes KA, Manolopoulos KN, Iqbal J, Cruden NL, Stimson RH, Reynolds RM, Newby DE,
479 Andrew R, Karpe F, Walker BR. Recycling between cortisol and cortisone in human splanchnic,
480 subcutaneous adipose, and skeletal muscle tissues in vivo. *Diabetes* 2012; 61:1357-1364
- 481 **36.** Goedhart G, Vrijkotte TG, Roseboom TJ, van der Wal MF, Cuijpers P, Bonnel GJ. Maternal
482 cortisol and offspring birthweight: results from a large prospective cohort study.
483 *Psychoneuroendocrinology* 2010; 35:644-652
- 484 **37.** Baibazarova E, van de Beek C, Cohen-Kettenis PT, Buitelaar J, Shelton KH, van Goozen SH.
485 Influence of prenatal maternal stress, maternal plasma cortisol and cortisol in the amniotic
486 fluid on birth outcomes and child temperament at 3 months. *Psychoneuroendocrinology*
487 2013; 38:907-915

Figure legends

Figure 1 a-b Model Schematic and Metabolism of deuterium-labelled glucocorticoids.

Model schematic showing the three compartments (maternal, syncytiotrophoblast and fetal; 1a) distinguished in the model. It is assumed that transfer between compartments is by simple diffusion, while metabolic conversion between cortisol and cortisone takes place in the syncytiotrophoblast (Equations. 1-6, see methods section). The input concentration of D4-cortisol in the maternal compartment varies over time according to the experimental protocol, while the input concentration in the fetal compartment is zero at all times. The output concentrations of the maternal and fetal compartments from the model can be compared to the experimental data.

D4-Cortisol is inactivated by 11β -HSD2 to D3-cortisone, with the loss of the deuterium on C11. 11β -HSD1 regenerates D3-cortisol from D3-cortisone, with the addition of an unlabeled hydrogen (1b).

Figure 2 a-f Model fit of experimental data.

In maternal circulation was 0-30 minutes EBB alone, 30-60 minutes EBB + 20nM D4-Cortisol, 60-90 minutes EBB + 200nM D4-Cortisol, 90-120 minutes EBB + 800nM D4-Cortisol, 120-150 minutes EBB + 800nM D₄F + 0.001M Carbenoxolone, 150-170 minutes EBB alone. The appearance of D4-cortisol in the fetal circulation is consistent with free transplacental passage of D4-cortisol. Inactivation of D4-cortisol by 11β -HSD2 is indicated by the appearance of D3-cortisone in the maternal or fetal circulations, and cortisol regeneration from D3-cortisone is indicated by the appearance of D3-cortisol.

Model fit of the experimental data for D4-cortisol in the maternal (2a) and fetal (2b) compartments, with a single set of parameters. Results show an excellent correspondence between model (straight line) and experiments (plotted data and error bars) ($R^2 = 0.99$). Model prediction of D3-cortisone in comparison with the scaled experimental data (2c-d). Note the experimental units for D3-cortisone could not be directly related to concentration and have been scaled here to allow comparison of the relative changes predicted by the model. The same conversion factor was applied to both maternal and fetal D3-cortisone based on the average ratio between experimental units and computed concentrations at the highest input level (time points $t = 110, 115$ and 120 min). Experimental data for D3-cortisol (2e-f). Values were comparatively low and were not modelled as they do not contribute significantly to the overall mass balance. All experimental results are the average of 5 placentas, expressed as mean and SEM ($n = 5$).

Key: D4F (D4-Cortisol), EBB (Earle's Bicarbonate Buffer), CBX (carbenoxolone).

Figure 3 Sensitivity analysis for D4-Cortisol transfer to the fetus as a function of variations in the model parameters.

The model parameters were varied with respect to the values for the reference fit. The reported changes in placental transfer predicted by the model were based on the steady state results at the highest maternal input concentration.

Key: k_{MVM} (MVM permeability constant), k_{BM} (BM permeability constant), V^{\max} (maximum rate of reaction), K_m (Michaelis-Menton constant), V_m (maternal compartment volume), V_s (syncytiotrophoblast compartment volume), V_f (fetal compartment volume), Q_m (maternal flow rate, L/min), Q_f (fetal flow rate, L/min).

Transfer and Metabolism of Cortisol by the Isolated Perfused Human Placenta

*Laura I Stirrat¹, *Bram G Sengers^{2,3}, Jane E Norman¹, Natalie Z.M Homer^{4,5}, Ruth Andrew^{4,5}, **Rohan M Lewis³ and **Rebecca M Reynolds^{1,5}

1. Tommy's Centre for Maternal and Fetal Health, MRC Centre for Reproductive Health, University of Edinburgh
2. Bioengineering Science Research Group, Faculty of Engineering and the Environment, University of Southampton, UK
3. Institute for Life Sciences, University of Southampton, UK.
4. Mass Spectrometry Core, Edinburgh Clinical Research Facility, University of Edinburgh, UK
5. University/BHF Centre for Cardiovascular Science, University of Edinburgh, UK

*joint first author

**joint last author

Supplementary Method

Details of the model equations and model parameters are described below.

1. Model equations

$$\frac{dC_A^m}{dt} = \frac{1}{v_m} \left(Q_m (C_A^{in,m} - C_A^m) - k_{MVM} (C_A^m - C_A^s) \right) \quad [1]$$

$$\frac{dC_A^s}{dt} = \frac{1}{v_s} \left(k_{MVM} (C_A^m - C_A^s) - k_{BM} (C_A^s - C_A^f) + J_A^{metab} \right) \quad [2]$$

$$\frac{dC_A^f}{dt} = \frac{1}{v_f} \left(k_{BM} (C_A^s - C_A^f) - Q_f C_A^f \right) \quad [3]$$

where C_A^m , C_A^s and C_A^f are the concentrations (mol/L) of solute A which can be either D4-cortisol (D4F), D3-cortisone (D3E) or D3-cortisol (D3F) in the maternal " m ", syncytiotrophoblast " s " and fetal " f " compartment respectively. Similarly, the volumes v (L) of the different compartments are indicated with subscripts using the same notation. Q_m and Q_f (L/min) are the fluid flow rates in the maternal and fetal circulation. $C_A^{in,m}$ is the maternal inlet concentration, which is zero for all solute species except D4-cortisol. Note that the fetal inlet concentration is zero for all species and therefore has not been included. k_{MVM} and k_{BM} denote the effective overall permeability constants (L/min) for the microvillous membrane (MVM) and basal membrane (BM) including surface area. These diffusive permeability constants were assumed to be the same for all solute species. The metabolic conversion rate J_A^{metab} (mol/min) depends on the solute species as follows:

$$J_{D4F}^{metab} = -\frac{V_{4F \rightarrow 3E}^{max} C_{D4F}^s}{K_m + C_{D4F}^s} \quad [4]$$

$$J_{D3E}^{metab} = \frac{V_{4F \rightarrow 3E}^{max} C_{D4F}^s}{K_m + C_{D4F}^s} - \frac{V_{3E \rightarrow 3F}^{max} C_{D3E}^s}{K_m + C_{D3E}^s} \quad [5]$$

$$J_{D3F}^{metab} = \frac{V_{3E \rightarrow 3F}^{max} C_{D3E}^s}{K_m + C_{D3E}^s} \quad [6]$$

where V^{max} (mol/min) is the maximum overall metabolic conversion rate and K_m (mol/L) is the Michaelis-Menten constant, i.e. the concentration at which half the maximum rate occurs.

2. Model parameters

The total cotyledon volume was based on the average cotyledon weight from the experiments (30.8×10^{-3} kg, $n = 5$), which was directly equated to the volume in L. The volume fractions of the maternal, syncytiotrophoblast and fetal compartments distinguished in the model were set to 34%, 15% and 7.4% respectively, as in our previous work. [14,22] The flow rates in the maternal and fetal circulations $Q_m = 14 \times 10^{-3}$ L/min and $Q_f = 6 \times 10^{-3}$ L/min were directly based on the experimental settings. To account for any discrepancies between nominal and actual values, the D4-cortisol input concentrations C_A^{in} used in the model were calculated based on the combined maternal and fetal steady state output during the blocking phase. The Michaelis-Menten constant K_m was set to 44×10^{-9} mol/L, based on the value for the enzyme 11 β -HSD2 for cortisol. [23] In first instance the same value was adopted for both metabolic conversion steps in Equations 4-6.

2. Parameter estimation

The remaining parameters in the model were determined by fitting the experimental data. The following error criterion was defined for a certain species A and compartment j in general:

$$R_A^j = \frac{1}{(\bar{C}_A^{exp,j})^2} \sum_{i \in T} (C_{A,i}^j - C_{A,i}^{exp,j})^2 \quad [7]$$

where $C_{A,i}^j$ and $C_{A,i}^{exp,j}$ are the computed and experimental concentrations at time point i , respectively, while $\bar{C}_A^{exp,j}$ is the mean of the experimental time points considered. The model was fitted to the steady state values after each change in maternal input concentration, including the blocking phase, therefore the set of time points T consisted of the last 4 time points for each different input phase (16 time points in total).

The D3-cortisol concentrations measured experimentally were 300 times smaller compared to D4-cortisol and did not contribute significantly to the overall mass balance. Therefore the conversion to D3-cortisol was neglected in the parameter estimation by setting $V_{3E \rightarrow 3F}^{max}$ to zero. In addition, the measured D3-cortisone values could not be directly related to concentration. Therefore D3-cortisone was not fitted, but instead the experimental values for D3-cortisone were scaled to allow comparison of the relative changes predicted by the model. Thus, only the D4-cortisol values in the maternal and fetal compartments (averaged over 5 placentas) were fitted according to the following overall error criterion:

$$R_{tot} = R_{D4F}^m + R_{D4F}^f \quad [8]$$

In total 3 parameters were fitted, the membrane permeability constants k_{MVM} and k_{BM} and the maximum rate of conversion from cortisol to cortisone $V_{4F \rightarrow 3E}^{max}$. Time integration of Equations 1-3 was performed in Matlab (R2016a) using the *ode45* function (Runge-Kutta (4, 5) method). Parameter estimation by minimising Eq. 8 was implemented using the *fminsearch* function (Nelder-Mead method). Initial parameter estimates were varied to verify that the algorithm converged to a unique solution.

Supplementary Tables

Supplementary Table 1 Mass spectral conditions for analysis of analytes and internal standards by positive ion electrospray ionisation

	Molecular Weight (amu)	Precursor ion (m/z)	Product ion (m/z) Quan; Qual	Declustering Potential (V)	Collision energy (V) Quan; Qual	Cell exit potential (V) Quan; Qual
ANALYTES						
D4-cortisol	367.0	367.0	121; only one	121	25	20
D3-cortisol	366.0	366.0	121.1; only one	121	25	20
D3-cortisone	363.2	364.2	164.0; only one	166	31	14
INTERNAL STANDARDS						
Epi-cortisol	363.2	363.2	121.0; 77.0	131	29; 101	14; 14

Abbreviations : Atomic mass units (amu) Quan (quantifier ion), Qual (qualifier ion), V (volts)


Supplementary Table 2 Inter-assay precision and accuracy

Concentrations of cortisol, cortisone, D4-Cortisol and D3-Cortisol were determined using calibration curves. Fourteen standards were prepared in 500 μ L EBB (range of concentrations 0.1 ng – 400 ng) enriched with internal standards (10 ng) along with blank samples were diluted in 500 μ L of water and processed using the same extraction method and analysis conditions as perfusate samples. Standard curves were plotted by calculating the peak area (analyte peak area / internal standard peak area). Weighting of 1/x and was applied to form standard curves of best fit with a regression coefficient above 0.99. The ion ratio (quantitative ion/qualitative ion) of the analytes was calculated using MultiQuant software and results were not considered acceptable if the ratio was greater than 20% of the ratio of the standards. Inter-assay fourteen point standard curve validation (n=6 different day respectively) was used to assess the limits of quantification of accuracy and precision for each analyte. Precision was based on the percentage relative standard deviation (%RSD), which was calculated using peak area ratios. Tissue sample* is intra-assay (amount, ng for tissue replicates (n=6). Inter-assay was not performed for tissue samples, as all tissue samples were analysed on the same day. Low values are the limit of quantification for each analyte.


		Concentration (ng/200 μ L perfusate or mg tissue*): mean (SD)	Precision (% RSD)	Accuracy (%)
D4-Cortisol	Low (0.2)	0.21 (0.02)	10.5	103
	Mid (50)	46.7 (1.7)	3.6	93
	High (400)	396.6 (43.4)	11.6	93
	Tissue Sample*	8.3 (0.6)	7.0	
D3-Cortisol	Low (0.1)	0.1 (0.02)	17.3	98
	Mid (10)	10.4 (0.9)	8.8	104
	High (20)	20.2 (2.0)	10.1	101
	Tissue Sample*	0.6 (0.04)	6.4	


Abbreviations: EBB (Earle's Bicarbonate Buffer), SD (Standard Deviation), RSD (Relative Standard Deviation)

1.a




1.b







Maternal Perfusion	Washout	20 nM D4F	200 nM D4F	800 nM D4F	800 nM D4F + CBX
--------------------	---------	-----------	------------	------------	------------------




Maternal Perfusion	Washout	20 nM D4F	200 nM D4F	800 nM D4F	800 nM D4F + CBX
--------------------	---------	-----------	------------	------------	------------------




Maternal Perfusion	Washout	20 nM D4F	200 nM D4F	800 nM D4F	800 nM D4F + CBX
--------------------	---------	-----------	------------	------------	------------------



Maternal Perfusion	Washout	20 nM D4F	200 nM D4F	800 nM D4F	800 nM D4F + CBX
--------------------	---------	-----------	------------	------------	------------------



Maternal Perfusion	Washout	20 nM D4F	200 nM D4F	800 nM D4F	800 nM D4F + CBX
--------------------	---------	-----------	------------	------------	------------------



Maternal Perfusion	Washout	20 nM D4F	200 nM D4F	800 nM D4F	800 nM D4F + CBX
--------------------	---------	-----------	------------	------------	------------------